SC-CAR4BRAIN
Phase 1Biologic
SC-CAR4BRAIN is one of 43 biologic programs targeting Diffuse Intrinsic Pontine Glioma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
57 competitors in Diffuse Intrinsic Pontine Glioma
#DrugCompanyPhaseTrials
1Verzenio
Eli LillyApproved
Aldara
BBausch Health Americas, Inc.
Approved
Caprelsa
GGenzyme, a Sanofi Company
Approved
Farydak
SSecuraBio
Approved
Afinitor
NovartisPhase 3
Theraplaza
BBiotech Pharmaceutical Co., Ltd.
Phase 3
ONC201
Jazz PharmaceuticalsPhase 3
Adriamycin
PfizerPhase 2
Depakote
AbbViePhase 2
Avastin
BBio-Thera Solutions
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SC-CAR4BRAIN. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- SSeattle Children's Hospital